Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. News
Sep 27, 2025 - globenewswire.com
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Jul 30, 2025 - globenewswire.com
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Jan 10, 2025 - zacks.com
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
Jan 6, 2025 - businesswire.com
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
Marinus Pharmaceuticals, Inc. Quantitative Score
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Marinus Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Marinus Pharmaceuticals, Inc. Financials
Table Compare
Compare MRNS metrics with: | |||
|---|---|---|---|
Earnings & Growth | MRNS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MRNS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MRNS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MRNS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Marinus Pharmaceuticals, Inc. Income
Marinus Pharmaceuticals, Inc. Balance Sheet
Marinus Pharmaceuticals, Inc. Cash Flow
Marinus Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Marinus Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. Scott N. Braunstein M.D. | Chief Executive Officer, President & Chairman |
| Mr. Steven E. Pfanstiel C.M.A., M.B.A. | Chief Operating Officer, Chief Financial Officer & Treasurer |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Molly Cameron | Director of Corporate Communications & Investor Relations |
| Ms. Martha E. Manning Esq., J. D. | Senior Vice President, General Counsel & Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Scott N. Braunstein M.D. | Chief Executive Officer, President & Chairman | 1963 | 1.01M | |
| Mr. Steven E. Pfanstiel C.M.A., M.B.A. | Chief Operating Officer, Chief Financial Officer & Treasurer | Male | 1973 | 670.25K |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer | 1957 | 665.47K | |
| Molly Cameron | Director of Corporate Communications & Investor Relations | -- | ||
| Ms. Martha E. Manning Esq., J. D. | Senior Vice President, General Counsel & Secretary | Female | 1955 | -- |
Marinus Pharmaceuticals, Inc. Insider Trades
| Date | 7 Feb |
| Name | Ezickson Elan |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 8600 |
| Date | 11 Feb |
| Name | Ezickson Elan |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 2300 |
| Date | 11 Feb |
| Name | Ezickson Elan |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10450 |
| Date | 11 Feb |
| Name | Ezickson Elan |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 20900 |
| Date | 11 Feb |
| Name | Ezickson Elan |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 16200 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Feb | Ezickson Elan | Director | Disposed | D-Return | 8600 |
| 11 Feb | Ezickson Elan | Director | Disposed | D-Return | 2300 |
| 11 Feb | Ezickson Elan | Director | Disposed | D-Return | 10450 |
| 11 Feb | Ezickson Elan | Director | Disposed | D-Return | 20900 |
| 11 Feb | Ezickson Elan | Director | Disposed | D-Return | 16200 |